In a report issued on January 18, Danielle Antalffy from Leerink Partners maintained a Buy rating on Cytosorbents (CTSO – Research Report). The company's shares closed last Wednesday at $3.42, close to its 52-week low of $3.18. According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 8.0% and a 49.3% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cytosorbents with a $16.00 average price target.
https://www.tipranks.com/news/blurbs/leerink-partners-thinks-cytosorbents-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more CytoSorbents Charts.
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more CytoSorbents Charts.